Preexposure prophylaxis for adolescents and young adults at risk for hiv infection: Is an ounce of prevention worth a pound of cure?

Clinical Infectious Diseases

Volumn 56, Issue 8, 2013, Pages 1149-1155

  Mayer, Kenneth H ^a   Pace, Jill E ^a   Siberry, George K ^a   Hazra, Rohan ^a   Kapogiannis, Bill G ^a  

^a EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

Author keywords

adolescents and young adults; HIV prevention; preexposure prophylaxis; PrEP

Indexed keywords

EMTRICITABINE PLUS TENOFOVIR DISOPROXIL;

ADULT; ARTICLE; BEHAVIORAL RESEARCH; BONE DENSITY; CONTROLLED STUDY; FRACTURE; HEADACHE; HIGH RISK BEHAVIOR; HIV TEST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; INTERVENTION STUDY; LIVER TOXICITY; MALE HOMOSEXUAL; NAUSEA; POST EXPOSURE PROPHYLAXIS; PREEXPOSURE PROPHYLAXIS; PRIORITY JOURNAL; RISK REDUCTION; SIDE EFFECT; VOMITING;

ADOLESCENT; ADULT; AFRICAN AMERICANS; ANTI-HIV AGENTS; COMMUNICABLE DISEASE CONTROL; FEMALE; HIV INFECTIONS; HOMOSEXUALITY, MALE; HUMANS; MALE; PRIMARY PREVENTION; RISK; UNITED STATES; YOUNG ADULT;

EID: 84875644597     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cis1020     Document Type: Article

References (45)

1. Joint United Nations Programme on HIV/AIDS. UNAIDS annual report 2009: uniting the world against AIDS, 2009. Geneva, Switzerland: UNAIDS; 2009.
2. Joint United Nations Programme on HIV/AIDS. Global report: UNAIDS report on the global AIDS epidemic, 2010. Geneva, Switzerland: UNAIDS; 2010.
3. Prejean J, Song R, Hernandez A, et al. Estimated HIV incidence in the United States, 2006-2009. PLoS One 2011; 6:e17502.
4. Flores SA, Bakeman R, Millett GA, Peterson JL. HIV risk among bisexually and homosexually active racially diverse young men. Sex Transm Dis 2009; 36:325-9.
5. Millett GA, Flores SA, Peterson JL, Bakeman R. Explaining disparities in HIV infection among black and white men who have sex with men: a meta-analysis of HIV risk behaviors. AIDS 2007; 21:2083-91. (Pubitemid 47462158)
6. Millett GA, Peterson JL, Wolitski RJ, Stall R. Greater risk for HIV infection of black men who have sex with men: a critical literature review. Am J Public Health 2006; 96:1007-19. (Pubitemid 43833153)
7. Baeten J, Celum C. Antiretroviral pre-exposure prophylaxis for HIV-1 prevention among heterosexual African men and women in Botswana: the Partners PrEP study. Rome, Italy: IAS, 2011.
8. Thigpen MC, Kebaabetswe PM, Smith DK, et al. Daily oral antiretroviral use for the prevention of HIV infection in heterosexually active young adults in Botswana: results from the TDF2 study. Rome, Italy: IAS, 2011.
9. Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med 2010; 363:2587-99.
10. Coates TJ, Richter L, Caceres C. Behavioural strategies to reduce HIV transmission: how to make them work better. Lancet 2008; 372: 669-84.
11. Metzger DS, Navaline H. HIV prevention among injection drug users: the need for integrated models. J Urban Health 2003; 80(4 suppl 3): iii59-66. (Pubitemid 38155477)
12. Marshall B, Evan W. Toward a comprehensive approach to HIV prevention for people who use drugs. J Acquir Immune Defic Syndr 2010; 55:S23-6.
13. Crepaz N, Lyles CM, Wolitski RJ, et al. Do prevention interventions reduce HIV risk behaviours among people living with HIV? A metaanalytic review of controlled trials. AIDS 2006; 20:143-57.
14. Semaan S, Kay L, Strouse D, et al. A profile of U.S.-based trials of behavioral and social interventions for HIV risk reduction. J Acquir Immune Defic Syndr 2002; 30(suppl 1):S30-50. (Pubitemid 34774063)
15. Centers for Disease Control and Prevention. Diffusion of evidence based interventions. Available at: http://www.effectiveinterventions. org/en/interventions.aspx. Accessed 12 December 2012.
16. Centers for Disease Control and Prevention. Tiers of evidence: a framework for classifying HIV behavioral interventions. Available at: http://www.cdc.gov/hiv/topics/research/prs/tiers-of-evidence.htm. Accessed 12 December 2012.
17. Ellen JM, Wallace M, Sawe FK, Fisher K. Community engagement and investment in biomedical HIV prevention research for youth: rationale, challenges, and approaches. J Acquir Immune Defic Syndr 2010; 54(suppl 1):S7-11.
18. Jaspan HB, Cunningham CK, Tucker TJ, et al. Inclusion of adolescents in preventive HIV vaccine trials: public health policy and research design at a crossroads. J Acquir Immune Defic Syndr 2008; 47:86-92. (Pubitemid 351619374)
19. Kapogiannis BG, Handelsman E, Ruiz MS, Lee S. Introduction: paving the way for biomedical HIV prevention interventions in youth. J Acquir Immune Defic Syndr 2010; 54(suppl 1):S1-4.
20. MacQueen KM, Karim QA. Practice brief: adolescents and HIV clinical trials: ethics, culture, and context. J Assoc Nurses AIDS Care 2007; 18:78-82.
21. McClure CA, Gray G, Rybczyk GK, Wright PF. Challenges to conducting HIV preventative vaccine trials with adolescents. J Acquir Immune Defic Syndr 2004; 36:726-33. (Pubitemid 38685967)
22. Ziff MA, Willard N, Harper GW, Bangi AK, Johnson J, Ellen JM. Connect to protect researcher-community partnerships: assessing change in successful collaboration factors over time. Glob J Community Psychol Pract 2010; 1:32-9.
23. DiClemente RJ, Ruiz MS, Sales JM. Barriers to adolescents' participation in HIV biomedical prevention research. J Acquir Immune Defic Syndr 2010; 54(suppl 1):S12-7.
24. Centers for Disease Control and Prevention. Interim guidance: preexposure prophylaxis for the prevention of HIV infection in men who have sex with men. MMWR Morb Mortal Wkly Rep 2011; 60:65-8.
25. CFR 46. Human subjects protection. Washington, D.C.: Department of Health and Human Services; 2009.
26. CFR 46 Subpart D. Additional protections for children involved as subjects in research. Washington, D.C.: Department of Health and Human Services; 2009.
27. CFR 50. Protection of human subjects. Washington, D.C.: Food and Drug Administration; 2012.
28. Eaton DK, Kann L, Kinchen S, et al. Youth risk behavior surveillance - United States, 2009. MMWR Surveill Summ 2010; 59:1-142.
29. Wilcox RD. Identification of HIV-infected youth and linkage to care can be major challenges. HIV Clin 2012; 24:1-2.
30. Woods JL, Shew ML, Tu W, Ofner S, Ott MA, Fortenberry JD. Patterns of oral contraceptive pill-taking and condom use among adolescent contraceptive pill users. J Adolesc Health 2006; 39:381-7. (Pubitemid 44224116)
31. Kahana SY, Rohan J, Allison S, Frazier TW, Drotar D. A meta-analysis of adherence to antiretroviral therapy and virologic responses in HIVinfected children, adolescents, and young adults. AIDS Behav 2012 [Epub ahead of print].
32. Mayer KH. Antiretrovirals and HIV prevention: new insights, challenges, and new directions. Curr Opin HIV AIDS 2012; 7:495-7.
33. Hammer SM, Eron JJ Jr., Reiss P, et al. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA 2008; 300:555-70.
34. Brown TT, McComsey GA, King MS, Qaqish RB, Bernstein BM, da Silva BA. Loss of bone mineral density after antiretroviral therapy initiation, independent of antiretroviral regimen. J Acquir Immune Defic Syndr 2009; 51:554-61.
35. McComsey GA, Tebas P, Shane E, et al. Bone disease in HIV infection: a practical review and recommendations for HIV care providers. Clin Infect Dis 2010; 51:937-46.
36. Stellbrink HJ, Orkin C, Arribas JR, et al. Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofoviremtricitabine in HIV-infected adults: 48-week results from the ASSERT study. Clin Infect Dis 2010; 51:963-72.
37. Hazra R, Siberry GK, Mofenson LM. Growing up with HIV: children, adolescents, and young adults with perinatally acquired HIV infection. Annu Rev Med 2010; 61:169-85.
38. Jacobson DL, Lindsey JC, Gordon CM, et al. Total body and spinal bone mineral density across Tanner stage in perinatally HIV-infected and uninfected children and youth in PACTG 1045. AIDS 2010; 24:687-96.
39. Mulligan K, Glidden D, Gonzales P, et al. Effects of FTC/TDF on bone mineral density in seronegative men from 4 continents: DEXA results of the global iPrEx study. Conference on Retroviruses and Opportunistic Infections; 27 February-2 March 2011; Boston, MA.
40. Galea JT, Kinsler JJ, Salazar X, et al. Acceptability of pre-exposure prophylaxis as an HIV prevention strategy: barriers and facilitators to pre-exposure prophylaxis uptake among at-risk Peruvian populations. Int J STD AIDS 2011; 22:256-62.
41. Juusola JL, Brandeau ML, Owens DK, Bendavid E. The cost-effectiveness of preexposure prophylaxis for HIV prevention in the United States in men who have sex with men. Ann Intern Med 2012; 156:541-50.
42. Matthews LT, Baeten JM, Celum C, Bangsberg DR. Periconception pre-exposure prophylaxis to prevent HIV transmission: benefits, risks, and challenges to implementation. AIDS 2010; 24:1975-82.
43. Paltiel AD, Freedberg KA, Scott CA, et al. HIV preexposure prophylaxis in the United States: impact on lifetime infection risk, clinical outcomes, and cost-effectiveness. Clin Infect Dis 2009; 48:806-15.
44. Pretorius C, Stover J, Bollinger L, Bacaer N, Williams B. Evaluating the cost-effectiveness of pre-exposure prophylaxis (PrEP) and its impact on HIV-1 transmission in South Africa. PLoS One 2010; 5: e13646.
45. Cruz H. Dear colleague letter. Albany, NY: New York Department of Health; 2012.